Holliston, Mass. – Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chief Financial Officer and Treasurer Jennifer Cote will resign effective upon the filing of the company’s Q1 2025 Form 10-Q, expected by May 12, 2025.
The company has named Mark Frost as Interim CFO and Treasurer, effective upon Cote’s departure. Frost, who has been consulting for Harvard Bioscience since January, brings over 30 years of financial leadership experience, including previous CFO roles at Fathom, Argon Medical Devices, and public healthcare companies such as Analogic, AngioDynamics, and AMRI.
“Mark is a proven financial executive with extensive experience in corporate finance and as a public company CFO,” said Jim Green, Chairman and CEO. “We are confident in his ability to lead our finance team through this transition.”
Green also thanked Cote for her contributions, highlighting her leadership on initiatives like the company’s recent ERP system consolidation.
